Charles Schwab Investment Management Inc. Grows Stock Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 193.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 148,114 shares of the company's stock after acquiring an additional 97,565 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.24% of Pulse Biosciences worth $2,598,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in PLSE. Price T Rowe Associates Inc. MD bought a new position in Pulse Biosciences in the 1st quarter valued at $88,000. Quest Partners LLC purchased a new stake in shares of Pulse Biosciences during the second quarter valued at $91,000. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences in the first quarter worth about $109,000. Rhumbline Advisers increased its stake in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock worth $288,000 after buying an additional 1,608 shares during the period. Finally, Creative Planning increased its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock worth $384,000 after buying an additional 11,667 shares during the period. Institutional investors own 76.95% of the company's stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research report on Thursday.

Pulse Biosciences Stock Up 8.6 %

Shares of NASDAQ PLSE traded up $1.52 during trading hours on Monday, reaching $19.17. The stock had a trading volume of 310,307 shares, compared to its average volume of 201,258. The business's fifty day moving average price is $17.68 and its two-hundred day moving average price is $16.45. Pulse Biosciences, Inc. has a 52-week low of $6.59 and a 52-week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period last year, the firm posted ($0.19) earnings per share.

Insider Buying and Selling

In other Pulse Biosciences news, Director Robert W. Duggan acquired 56,054 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average price of $17.35 per share, with a total value of $972,536.90. Following the completion of the purchase, the director now directly owns 42,228,057 shares of the company's stock, valued at approximately $732,656,788.95. This represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 71.50% of the stock is owned by insiders.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.